Background: The combination of prediabetes and depressive or anxiety symptoms is known to increase the risk of progression to diabetes. We aimed to assess the effects of vitamin D supplementation on anxiety and depression status among elderly people with prediabetes.

Methods: Participants were randomly assigned to a weekly dose of vitamin D3 of 25,000 IU (n=45) or nothing (n = 45) , in addition to lifestyle measures. The State Trait Anxiety Inventory and the Patient Health Questionnaire-9 (PHQ-9) tools were used to evaluate anxiety and depression levels, respectively, at baseline, 6 and 12 months.

Results: Participants in the intervention and control group presented comparable baseline characteristics in terms of age (73.± 7.16 vs. 74.03 ± 7.64 years, respectively) , fasting glucose (103.4 ± 12.vs. 102.29 ± 12.82 mg/dl, respectively) and HbA1c values (5.87 ± 0.21 vs. 5.87 ± 0.22 %, respectively) . In the supplemented group, 25-hydroxyvitamin D concentrations increased significantly at 6 (26.56 ± 8.64 ng/ml) and 12 months (28.71 ± 9.03 ng/ml) compared to baseline (19.98 ± 6.73 ng/ml, p<0.0 for both comparisons) . The mean trait anxiety scores were lower in supplemented individuals than the control group at 6 (38.02 ± 9.03 vs. 43.91 ± 7.18, respectively, p=0.003) and 12 months (32.35 ± 7.77 vs. 44.97 ± 7.78, respectively, p<0.001) . The same pattern was evident for state anxiety scores at 6 (37.± 7.88 vs. 43.20 ± 9.33, p=0.003) and 12 months (32.59 ± 6.45 vs. 44.60 ± 9.53, p<0.001) . Supplemented participants demonstrated lower mean PHQ-9 scores compared with controls at 6 (15.69 ± 6.15 vs. 19.77 ± 8.96, respectively, p=0.021) and 12 months (13.52 ± 5.vs. 20.20 ± 8.67, respectively, p<0.001) .

Conclusion: In a high-risk population, a weekly vitamin D supplementation scheme was effective in reducing anxiety and depression levels. Further studies are needed to elucidate the relevant mechanisms.

Disclosure

E.Zaromytidou: None. M.Grammatiki: Research Support; Lilly. E.Manthou: None. I.S.Psarrakou: None. I.Iakovou: None. A.Gotzamani: None. K.Kotsa: Advisory Panel; Abbott, Novo Nordisk, Research Support; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Speaker's Bureau; AstraZeneca, Merck Sharp & Dohme Corp., Novartis AG, Sanofi. T.Koufakis: Advisory Panel; Novo Nordisk, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk. G.Dimakopoulos: None. D.Drivakou: None. G.Meristoudis: None. S.Konstantinidou: None. G.Karaliolios: None. E.Melidou: None. P.Rakitzi: None.

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.